Fore Biotherapeutics

Formerly known as NovellusDX




Series C


Founded in 2011, NovellusDX has brought together a team of skilled individuals from several fields, including synthetic biology, functional genomics, bioinformatics, engineering, algorithm development, clinical laboratory and healthcare commercialization. Together, they lead the companys mission to deliver evidence-based clinical insights and enable oncology professionals to treat every cancer and each patient with the precise treatment and to support pharmaceutical companies with their drugs life cycle.Genome sequencing techniques reveal mutations but provide no knowledge whether the translated protein is actually aberrantly activated. This is because the functional significance of most mutations is unknown, let alone that of networks of interacting proteins. NovellusDx leverages its live cell based assay to complement the power of NGS with actionable insights on the affected signaling pathways.

Michael VidneCEO
Haim Gil-Ad

Roberto De PontiHead, Corporate N…1

Investor NameInvestor TypeAUM ($)
Bio Capital Impact FundVenture Capital0
Cormorant Asset ManagementHedge Fund900,000,000
HBM Healthcare InvestmentsInvestment Firm0
Helsinn Investment FundInvestment Firm0
Novartis Venture FundCorporate Venture Capital800,000,000
OrbiMedVenture Capital15,000,000,000
PontifaxVenture Capital600,000,000
SR OneCorporate Venture Capital1,000,000,000
Wellington ManagementInvestment Firm0
Windham Venture PartnersVenture Capital0


Utilizing advanced machine learning methods on a proprietary datasets of cell images, we learn and assign the functional significance to unknown mutations. Accurate prediction of the signaling pathway activity elicited by Variants of Uncertain Significance (VUS) and their drug sensitivity using Deep Convolutional Neural Networks on fluorescent microscopy images of cells.

Sign up for free

  • Save profiles to your list
  • Basic search functionality